Share on LinkedInShare on LinkedIn

ARTICLE · 25 JUNE 2018

The Proposed SPC Export Manufacturing Waiver: Really A Balanced Approach?

Jones Day
Jones Day
Contributor
Jones Day

Jones Day

Jones Day is a global law firm with more than 2,400 lawyers in 40 offices across five continents....

View firm profile
Explore more from Jones Day

The proposed amendment to the European regulation 469/2009 concerning the supplementary protection certificate for medicinal products would introduce an exception to the scope of protection...

European UnionIntellectual Property

In Short

The Situation: For the pharmaceutical industry, supplementary protection certificates ("SPC") are probably the most valuable IP rights. While the scope of protection of an SPC is determined separately from the scope of protection of the underlying basic patent, it is similar to the basic patent in that it functionally does not distinguish between manufacturing for domestic use and for use in (patent free) countries. Thus, under the current law, manufacturing for export purposes infringes the rights of the SPC owner.

The Plan: To counter a perceived potential loss of export markets, the European Commission proposes to introduce an "export manufacturing waiver" that would limit the scope of SPCs in Europe where patented products are being manufactured for export to countries outside the EU.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from